Travel Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Composition, Application, Disease Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Travel Vaccines Market size was around USD 5.64 Billion in 2026 and is slated to grow at 10.49% CAGR from 2027 to 2036, surpassing USD 15.29 Billion by 2036. The industry revenue for 2027 is calculated at USD 6.14 Billion.
Get more details on this report
Request Free Sample ReportTravel Vaccines Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 46.53% share in 2026, supported by established vaccination infrastructure, high health-risk awareness, and broad access to travel healthcare services.
- Asia Pacific is the fastest-growing region, supported by increasing international travel, rising preventive healthcare awareness, improving healthcare access, and expanding travel health services.
Segment Momentum
- Mono vaccines accounted for 62.75% of the market in 2026 because they provide targeted protection against destination-specific diseases, offer flexible immunization schedules, and are widely recommended for individual travel requirements.
- The yellow fever segment is expected to grow the fastest as travel to endemic regions increases and mandatory vaccination requirements for entry into several countries drive higher vaccine uptake.
Market Expansion Drivers
- Rising international travel volumes increasing demand for preventive vaccination services
- Growing awareness of infectious disease prevention supporting pre-travel immunization uptake
- Advancements in vaccine development improving efficacy and accessibility of travel immunizations
Leading Market Participants
- Major companies in the travel vaccines market include GlaxoSmithKline plc (United Kingdom), Sanofi S.A. (France), Pfizer Inc. (United States), Merck & Co., Inc. (United States), CSL Limited (Australia), Bharat Biotech International Limited (India), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Valneva SE (France), Emergent BioSolutions Inc. (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.64 Billion
- 2027 Estimated Market Size: USD 6.14 Billion
- Projected Market Size: USD 15.29 Billion by 2036
- Growth Forecast: 10.49% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Mono Vaccines (Composition) | Outbound Travel (Application) | Hepatitis a (Disease Type)
- Emerging Opportunity Segment: Combination Vaccines (Composition) | Outbound Travel (Application) | Yellow Fever (Disease Type)
Market Growth Drivers and Industry Trends
Rising international travel volumes increasing demand for preventive vaccination services
As international mobility continues to expand for tourism, business, education, and humanitarian activities, the travel vaccines market is experiencing stronger demand for preventive immunization services. Travelers visiting destinations with region-specific infectious disease risks increasingly seek recommended vaccinations before departure to reduce health complications during travel. Healthcare providers and travel clinics are integrating vaccination consultations into pre-travel healthcare planning, making preventive immunization an essential component of international travel preparation.
Growing awareness of infectious disease prevention supporting pre-travel immunization uptake
Greater public understanding of communicable disease risks will propel the travel vaccines market growth by encouraging travelers to adopt preventive healthcare measures before visiting international destinations. Educational campaigns, physician recommendations, and readily available travel health information have increased awareness of the importance of vaccination against diseases that may not be prevalent in travelers' home countries. This heightened awareness supports earlier healthcare consultations and broader acceptance of recommended immunization schedules prior to travel.
Advancements in vaccine development improving efficacy and accessibility of travel immunizations
Continuous innovation in vaccine research is strengthening the travel vaccines market by improving the effectiveness, safety, and availability of immunizations designed for international travelers. Advances in formulation technologies, manufacturing processes, and delivery methods are helping healthcare providers offer vaccines with enhanced protection and more convenient administration. These improvements support broader access to preventive vaccination services while enabling travel medicine specialists to address evolving infectious disease risks across diverse geographic regions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising international travel volumes increasing demand for preventive vaccination services | 2.4% | High | North America, Europe | High | Near Term |
| Growing awareness of infectious disease prevention supporting pre-travel immunization uptake | 2.1% | High | Asia Pacific, North America | High | Near Term |
| Advancements in vaccine development improving efficacy and accessibility of travel immunizations | 1.9% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The travel vaccines market was led by North America, which held a 46.53% share in 2026, reflecting strong demand for preventive healthcare among international travelers and well-established vaccination infrastructure. High awareness of travel-related health risks encourages travelers to seek recommended immunizations before visiting destinations where infectious diseases may present greater exposure. The region benefits from established healthcare systems, broad access to vaccination services, and greater integration of travel health guidance into pre-travel medical consultations. International business travel, tourism, and other forms of cross-border mobility also contribute to demand for vaccines targeting travel-associated infections. Continued emphasis on preventive healthcare and traveler safety is expected to sustain regional demand for travel vaccination services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region in the travel vaccines market, supported by increasing international travel, expanding tourism activity, and growing awareness of preventive healthcare. Rising outbound travel from the region is encouraging more individuals to seek pre-travel medical advice and vaccination, particularly when visiting destinations with different infectious disease profiles. Improvements in healthcare access and increasing public awareness of immunization are also supporting broader adoption. The expansion of medical and travel health services is making preventive vaccination more accessible to travelers, while increasing disposable incomes are enabling greater spending on travel-related healthcare. Growing cross-border mobility and continued development of healthcare infrastructure are expected to provide further momentum to the regional market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Preventive Health AdoptionThe U.S. travel vaccines market is supported by growing awareness of destination-specific immunization requirements among international travelers. Healthcare providers across the U.S. continue expanding travel health services that integrate vaccination, consultation, and digital appointment management.
Germany 🇩🇪
Structured Immunization ServicesGermany emphasizes organized travel vaccination programs delivered through healthcare providers and pharmacies. Travelers in Germany increasingly seek destination-based preventive guidance, encouraging broader adoption of recommended immunization schedules before international travel.
Japan 🇯🇵
Outbound Travel PreparednessJapan prioritizes travel vaccines as international mobility increases across business and leisure travel segments. Healthcare institutions in Japan continue strengthening traveler education and pre-departure vaccination services to improve preventive healthcare practices.
South Korea 🇰🇷
Digital Travel Health AccessSouth Korea supports travel vaccine uptake through digitally enabled healthcare services and expanding international travel activity. Medical providers in South Korea increasingly integrate appointment scheduling and travel health consultations with vaccination programs for greater convenience.
France 🇫🇷
Public Health ComplianceFrance maintains strong demand for travel vaccines through established preventive healthcare practices and destination-specific immunization guidance. Healthcare professionals in France continue promoting timely vaccination to reduce travel-related infectious disease risks.
Italy 🇮🇹
Traveler Immunization PlanningItaly focuses on improving access to travel vaccines through coordinated healthcare consultations and increasing awareness of international travel health requirements. Travelers in Italy increasingly incorporate recommended vaccinations into pre-travel planning for both business and leisure journeys.
Segment Leadership and Growth Trends
Travel Vaccines Market Share (%), by Composition, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportComposition Segment Analysis: Mono Vaccines (Largest Segment) vs Combination Vaccines (Fastest-Growing Segment)
The travel vaccines market was led by the mono vaccines segment, which accounted for 62.75% of the market share in 2026. Its dominance is supported by the widespread administration of disease-specific vaccines tailored to destination-related health risks and individual traveler requirements. Healthcare providers frequently recommend mono vaccines due to their established clinical effectiveness, flexible immunization schedules, and suitability for travelers requiring protection against specific infectious diseases based on regional exposure.
The combination vaccines segment is anticipated to witness the fastest growth over the forecast period. Increasing international travel, rising awareness of preventive healthcare, and the need to simplify vaccination schedules are encouraging greater adoption of combination vaccines. Their ability to provide protection against multiple diseases through fewer injections enhances patient compliance, reduces clinic visits, and supports more efficient pre-travel immunization programs.
Application Segment Analysis: Outbound Travel (Largest & Fastest-Growing Segment)
Holding the largest share of the travel vaccines market, the outbound travel segment captured 62.69% of the market share in 2026 while also emerging as the fastest-growing application. Rising international tourism, business travel, educational mobility, and religious travel continue to increase demand for destination-specific immunization. Governments and healthcare providers are placing greater emphasis on preventive vaccination before overseas travel, while evolving international health regulations and heightened awareness of travel-related infectious diseases further reinforce the segment's leading position.
Disease Type Segment Analysis: Hepatitis a (Largest Segment) vs Yellow Fever (Fastest-Growing Segment)
The hepatitis A segment accounted for 21.82% of the market share in 2026, supported by its importance as one of the most frequently recommended travel vaccinations for destinations with elevated risks of food- and water-borne infections. Increasing awareness among travelers, established immunization guidelines, and the vaccine's proven effectiveness in preventing infection continue to sustain strong demand across travel medicine programs.
The travel vaccines market is expected to experience the fastest growth in the yellow fever segment due to expanding travel to endemic regions and mandatory vaccination requirements for entry into several countries. Greater compliance with international travel regulations, rising participation in cross-border travel, and increased public health initiatives promoting vaccination before travel are contributing to the rapid expansion of this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Composition | Mono Vaccines, Combination Vaccines | Mono Vaccines | Combination Vaccines |
| Application | Outbound Travel, Domestic Travel | Outbound Travel | Outbound Travel |
| Disease Type | Hepatitis A, Hepatitis B, Influenza, Diphtheria Pertussis Tetanus (DPT), Rabies, Yellow Fever, Typhoid, Measles and Mumps, Meningococcal, Others | Hepatitis a | Yellow Fever |
Competitive Landscape and Market Positioning
Key companies in the travel vaccines market:
- GlaxoSmithKline plc (United Kingdom)
- Sanofi S.A. (France)
- Pfizer, Inc. (United States)
- Merck & Co., Inc. (United States)
- CSL Limited (Australia)
- Bharat Biotech International Limited (India)
- Serum Institute of India Pvt. Ltd. (India)
- Bavarian Nordic A/S (Denmark)
- Valneva SE (France)
- Emergent BioSolutions, Inc. (United States)
Rivalry across the travel vaccines market is becoming more closely tied to the breadth and accessibility of immunization services than to vaccine availability alone. Providers that can support travelers with convenient scheduling, integrated travel health guidance, and reliable supply continuity are strengthening their competitive position as international mobility expands. At the same time, increasing awareness of destination-specific health risks is encouraging broader investment in educational resources and preventive healthcare capabilities, making clinical expertise and service quality important competitive distinctions. Regulatory compliance, distribution reliability, and the ability to respond efficiently to changing travel health requirements further influence how participants strengthen their presence across different regions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc (United Kingdom) | |||||||
| Sanofi S.A. (France) | |||||||
| Pfizer Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| CSL Limited (Australia) | |||||||
| Bharat Biotech International Limited (India) | |||||||
| Serum Institute of India Pvt. Ltd. (India) | |||||||
| Bavarian Nordic A/S (Denmark) | |||||||
| Valneva SE (France) | |||||||
| Emergent BioSolutions Inc. (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Bavarian Nordic | Jun-26 | Bavarian Nordic secured Health Canada approval for its recombinant chikungunya vaccine, VIMKUNYA. The regulatory clearance expands the firm's commercial footprint in North America and strengthens its specialized travel health portfolio by providing broad consumer access to chikungunya prevention. |
| Bavarian Nordic | Jan-26 | Bavarian Nordic entered into a strategic distribution agreement with Eurofarma to commercialize its chikungunya vaccine in Brazil. The partnership bolsters the company's regional logistics infrastructure and accelerates market penetration of its travel vaccine assets across the Latin American market. |
| Bavarian Nordic | Feb-25 | Bavarian Nordic received U.S. FDA approval for its single-dose chikungunya vaccine, VIMKUNYA, for individuals aged 12 and older. The authorization significantly expands the company's travel vaccine portfolio and enhances its competitive position as the first approved chikungunya vaccine for a pediatric population. |
| Valneva | Feb-25 | Valneva obtained a marketing authorization grant from the UK Medicines and Healthcare products Regulatory Agency for its single-dose chikungunya vaccine, IXCHIQ, for individuals aged 18 and older. The approval establishes a commercial entry point in the UK market for emerging travel health threats. |
| Takeda | Feb-24 | Takeda formalized a strategic manufacturing partnership with Biological E to accelerate the global production and availability of QDENGA, its dengue tetravalent vaccine. The collaboration addresses supply chain scalability requirements amid rising global travel and escalating public health demand for dengue prevention. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Travel Vaccines Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Traveler Type | Leisure Travelers, Business Travelers, Visiting Friends and Relatives (VFR), Adventure and Expedition Travelers |
| Vaccine Technology | Live Attenuated, Inactivated, Recombinant/Subunit, Conjugate, Toxoid |
| Payer Type | Out-of-Pocket, Private Insurance, Public/Government Programs, Employer-Sponsored |
Travel Vaccines Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Traveler Risk Profiling & Immunization Needs |
|
| Travel Clinic Channel Strategy |
|
| Vaccination Access & Affordability |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the travel vaccines market generate?
How much is the travel vaccines industry expected to grow by 2036?
How is international travel influencing demand in the travel vaccines market?
Why are advancements in vaccine development important for the travel vaccines market?
Why do mono vaccines dominate the travel vaccines market?
Which disease type is expected to grow the fastest in the travel vaccines market?
What makes North America the leading travel vaccines market?
Why is Asia Pacific expected to grow rapidly in travel vaccines?
What are the prominent companies operating in the travel vaccines landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization